BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.335
-0.210 (-38.59%)
Nov 21, 2024, 1:57 PM EST - Market open

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $44.57 million. The enterprise value is $35.71 million.

Market Cap 44.57M
Enterprise Value 35.71M

Important Dates

The next confirmed earnings date is Monday, November 25, 2024, before market open.

Earnings Date Nov 25, 2024
Ex-Dividend Date n/a

Share Statistics

BioLineRx has 1.20 billion shares outstanding. The number of shares has increased by 22.24% in one year.

Current Share Class n/a
Shares Outstanding 1.20B
Shares Change (YoY) +22.24%
Shares Change (QoQ) +10.21%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 1.09B

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio n/a
P/TBV Ratio 153.17
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.09
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 2.24.

Current Ratio 1.61
Quick Ratio 1.44
Debt / Equity 2.24
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -12.03

Financial Efficiency

Return on equity (ROE) is -171.94% and return on invested capital (ROIC) is -54.52%.

Return on Equity (ROE) -171.94%
Return on Assets (ROA) -35.23%
Return on Capital (ROIC) -54.52%
Revenue Per Employee $215,797
Profits Per Employee -$381,253
Employee Count 79
Asset Turnover 0.28
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -79.99% in the last 52 weeks. The beta is 0.87, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y) 0.87
52-Week Price Change -79.99%
50-Day Moving Average 0.50
200-Day Moving Average 0.73
Relative Strength Index (RSI) 34.27
Average Volume (20 Days) 799,077

Short Selling Information

Short Interest 1.06M
Short Previous Month 621,386
Short % of Shares Out 1.33%
Short % of Float n/a
Short Ratio (days to cover) 2.39

Income Statement

In the last 12 months, BioLineRx had revenue of $17.05 million and -$30.12 million in losses. Loss per share was -$0.03.

Revenue 17.05M
Gross Profit 11.00M
Operating Income -34.82M
Pretax Income -49.15M
Net Income -30.12M
EBITDA -33.08M
EBIT -34.82M
Loss Per Share -$0.03
Full Income Statement

Balance Sheet

The company has $40.06 million in cash and $31.26 million in debt, giving a net cash position of $8.81 million or $0.01 per share.

Cash & Cash Equivalents 40.06M
Total Debt 31.26M
Net Cash 8.81M
Net Cash Per Share $0.01
Equity (Book Value) 13.98M
Book Value Per Share 0.01
Working Capital 18.59M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$30.35 million and capital expenditures -$76,000, giving a free cash flow of -$30.42 million.

Operating Cash Flow -30.35M
Capital Expenditures -76,000
Free Cash Flow -30.42M
FCF Per Share -$0.03
Full Cash Flow Statement

Margins

Gross margin is 64.55%, with operating and profit margins of -204.22% and -176.67%.

Gross Margin 64.55%
Operating Margin -204.22%
Pretax Margin -176.67%
Profit Margin -176.67%
EBITDA Margin -194.04%
EBIT Margin -204.22%
FCF Margin -247.25%

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -22.24%
Shareholder Yield -22.24%
Earnings Yield -67.57%
FCF Yield -68.26%

Analyst Forecast

The average price target for BioLineRx is $11.50, which is 3,286.34% higher than the current price. The consensus rating is "Strong Buy".

Price Target $11.50
Price Target Difference 3,286.34%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on July 15, 2019. It was a reverse split with a ratio of 0.0666666:1.

Last Split Date Jul 15, 2019
Split Type Reverse
Split Ratio 0.0666666:1

Scores

BioLineRx has an Altman Z-Score of -8.56. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -8.56
Piotroski F-Score n/a